Back to top
more

Ethos Technologies Inc. (LIFE)

(Real Time Quote from BATS)

$39.41 USD

39.41
1,043,804

+0.85 (2.20%)

Updated Aug 26, 2026 01:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 16% (208 out of 247)

Industry: Insurance - Life Insurance

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of 55.77% and 347.63%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

5 Top Stocks to Play Earnings Beat Potential

by Sanghamitra Saha

These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap American Woodmark (AMWD), Skechers (SKX), Workday (WDAY), aTyr Pharma (LIFE) and Modine Manufacturing (MOD).

Zacks Equity Research

Down -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE)

by Zacks Equity Research

Atyr Pharma (LIFE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Sanghamitra Saha headshot

5 Top Stocks Likely to Top Earnings Estimates

by Sanghamitra Saha

Top-ranked stocks Yum China (YUMC), Amazon.com (AMZN), Workday (WDAY), aTyr Pharma (LIFE) and D.R. Horton (DHI) are likely to beat on the bottom line in their upcoming releases.

Zacks Equity Research

Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 18.52% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 25.64% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Atyr Pharma (LIFE) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Atyr Pharma (LIFE) delivered earnings and revenue surprises of -29.41% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?